For the Inventor, By the Inventor

Enter assignee name

Hwaseong, South Korea

Hanmi Pharm. Co., Ltd.

USPTO Granted Patents = 148

% Expired Patents = 29.7

CIPO Patents = 5

EPO Patents = 67

Forward Citations = 471

Loading Chart...

Loading Chart...

250 inventors (with patents filed for the assignee):

Se Chang Kwon (44 out of 90 patents)

Sung Youb Jung (36 out of 63 patents)

In Young Choi (20 out of 31 patents)

4. Kwee Hyun Suh (19 out of 25 patents)

5. Gwan-Sun Lee (19 out of 23 patents)

6. Jong Soo Woo (18 out of 21 patents)

7. Sung Min Bae (17 out of 31 patents)

8. Dae Jin Kim (17 out of 34 patents)

9. Young Gil Ahn (16 out of 23 patents)

10. Young Jin Park (15 out of 89 patents)

11. Jae Hyun Park (15 out of 129 patents)

12. Yong Il Kim (14 out of 75 patents)

13. In Hwan Bae (13 out of 14 patents)

14. Gwan Sun Lee (13 out of 44 patents)

15. Hyung Kyu Lim (12 out of 13 patents)

Core Competencies:

Pharmaceutical Composition

Insulin Analogs

Glucagon Derivatives

Cancer Treatments

Protein Complexes

Long-Acting Conjugates

Immunoglobulin Fragments

Enzyme Fusion Proteins

Pyrimidine Compounds

Therapeutic Use

Drug Conjugates

Neutropenia Treatments

148 patents: Sort by Forward Citations

1. 12508298 - PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE (2025-12-30),

2. 12491258 - NOVEL METHOD FOR PREPARING LONG-ACTING DRUG CONJUGATE THROUGH PREPARATION OF INTERMEDIATE (2025-12-09),

3. 12479845 - Imidazopyridine derivative compounds and use of same (2025-11-25),

4. 12435328 - Therapeutic enzyme fusion protein having a novel structure and use thereof (2025-10-07),

5. 12433867 - Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia (2025-10-07),

6. 12415842 - Immunostimulating IL-2 analogs (2025-09-16),

7. 12390533 - Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor (2025-08-19),

8. 12350315 - Methods of treating neutorpenia using G-CSF protein complex (2025-07-08),

9. 12350265 - Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents (2025-07-08),

10. 12325698 - Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same (2025-06-10),

11. 12319695 - Sulfonamide derivative with fused pyrimidine skeleton, having epidermal growth factor receptor mutation inhibitory effect (2025-06-03),

12. 12318430 - Methods of treating neutorpenia using G-CSF protein complex (2025-06-03),

13. 12274750 - Lyophilized formulation of long-acting human growth hormone immunoglobulin conjugate (2025-04-14),

14. 12227510 - Crystal form of acid addition salt of furopyrimidine compound (2025-02-18),

15. 12139455 - Polyethylene glycol derivative and use thereof (2024-11-12),

Company Overview

Hanmi Pharm. Co., Ltd., based in Hwaseong, South Korea, specializes in the development and manufacturing of innovative pharmaceutical compositions. The company focuses on advanced therapeutic areas, including insulin analogs, glucagon derivatives, and cancer treatments. Hanmi is recognized for its expertise in protein complexes, long-acting conjugates, immunoglobulin fragments, and enzyme fusion proteins, positioning itself as a key player in the pharmaceutical industry with a commitment to improving patient outcomes through cutting-edge research and technology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

148 Patents

#2 in Hwaseong

#149 in South Korea

#5,531 in the World

Hwaseong, South Korea

Hanmi Pharm. Co., Ltd.

Forward Citations = 471

250 inventors:

Se Chang Kwon (44 out of 90 patents)

Sung Youb Jung (36 out of 63 patents)

In Young Choi (20 out of 31 patents)

4. Kwee Hyun Suh (19 out of 25 patents)

5. Gwan-Sun Lee (19 out of 23 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Hanmi Pharm. Co., Ltd.. Retrieved from https://idiyas.com/company/hanmi-pharm-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…